15 patents
Utility
5- and 6-AZAINDOLE Compounds for Inhibition of Bcr-abl Tyrosine Kinases
30 Nov 23
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
Filed: 11 Aug 23
Utility
Fused Tetracyclic Quinazoline Derivatives As Inhibitors of ERBB2
30 Nov 23
The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN, Qiang SU
Filed: 15 May 23
Utility
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
7 Nov 23
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Joseph P. Lyssikatos, Samuel Kintz, Li Ren
Filed: 13 Dec 22
Utility
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
7 Nov 23
The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
Joseph P. Lyssikatos, Samuel Kintz, Li Ren, Qiang Su
Filed: 1 Nov 22
Utility
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
26 Sep 23
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Joseph P. Lyssikatos, Samuel Kintz, Li Ren
Filed: 4 Oct 21
Utility
Fused Tetracyclic Quinazoline Derivatives As Inhibitors of ERBB2
25 May 23
The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN, Qiang SU
Filed: 1 Nov 22
Utility
5- and 6-AZAINDOLE Compounds for Inhibition of Bcr-abl Tyrosine Kinases
27 Apr 23
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
Filed: 13 Dec 22
Utility
5- and 6-AZAINDOLE Compounds for Inhibition of Bcr-abl Tyrosine Kinases
2 Mar 23
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Joseph P. LYSSIKATOS, Samuel KINTZ, Li REN
Filed: 4 Oct 21
Utility
PDE9 Inhibitors for Treating Thalassemia
17 Feb 22
The present disclosure relates to PDE9 inhibitors, compositions comprising the PDE9 inhibitors, and methods of using the PDE9 inhibitors and compositions for treatment of thalassemia.
Rahul Dilip BALLAL, Thiago Trovati MACIEL
Filed: 29 Oct 21
Utility
PDE9 Inhibitors for Treating Sickle Cell Disease
27 Jan 22
The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
Niels SVENSTRUP, David TISI, Jeffrey WORTHINGTON, Vanik PETROSSIAN
Filed: 4 Oct 21
Utility
Treatment of Pulmonary Arterial Hypertension Using Therapeutically Effective Oral Doses of 10-NITRO-9(E)-OCTADEC-9-ENOIC Acid
6 Jan 22
Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension.
Diane JORKASKY
Filed: 19 Mar 21
Utility
PDE9 Inhibitors for Treating Sickle Cell Disease
17 Jun 21
The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
Edward George CALAMAI, Deborah Lynn Leithead DOBBINS, Michael Paul DEHART, James MCARTHUR, Shi Yin FOO
Filed: 26 Feb 21
Utility
PDE9 Inhibitors for Treatment of Peripheral Diseases
25 Mar 21
The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
Niels Svenstrup, Anna I. Parachikova, James McArthur
Filed: 9 Oct 20
Utility
Methods of Making and Using PDE9 Inhibitors
20 May 20
The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
Niels SVENSTRUP, Jun ZHANG, Jikui SUN, Yuyin CHEN, Jianshe KONG, Rujian MA, Junhua ZHANG, Liang QIN, Huanming XIAO, Jinxu SUN, Xiao MENG, Fenglai SUN, Jingyang ZHU
Filed: 24 May 18
Utility
PDE9 Inhibitors for Treatment of Peripheral Diseases
9 Oct 19
The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.
Niels Svenstrup, Anna I. Parachikova, James McArthur
Filed: 29 Jun 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first